» Articles » PMID: 33845808

Reference-free Transcriptome Signatures for Prostate Cancer Prognosis

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2021 Apr 13
PMID 33845808
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: RNA-seq data are increasingly used to derive prognostic signatures for cancer outcome prediction. A limitation of current predictors is their reliance on reference gene annotations, which amounts to ignoring large numbers of non-canonical RNAs produced in disease tissues. A recently introduced kind of transcriptome classifier operates entirely in a reference-free manner, relying on k-mers extracted from patient RNA-seq data.

Methods: In this paper, we set out to compare conventional and reference-free signatures in risk and relapse prediction of prostate cancer. To compare the two approaches as fairly as possible, we set up a common procedure that takes as input either a k-mer count matrix or a gene expression matrix, extracts a signature and evaluates this signature in an independent dataset.

Results: We find that both gene-based and k-mer based classifiers had similarly high performances for risk prediction and a markedly lower performance for relapse prediction. Interestingly, the reference-free signatures included a set of sequences mapping to novel lncRNAs or variable regions of cancer driver genes that were not part of gene-based signatures.

Conclusions: Reference-free classifiers are thus a promising strategy for the identification of novel prognostic RNA biomarkers.

Citing Articles

Genomic strategies for drug repurposing.

Dave K, Patel D, Dave N, Jain M J Egypt Natl Canc Inst. 2024; 36(1):35.

PMID: 39523244 DOI: 10.1186/s43046-024-00245-z.


A survey of k-mer methods and applications in bioinformatics.

Moeckel C, Mareboina M, Konnaris M, Chan C, Mouratidis I, Montgomery A Comput Struct Biotechnol J. 2024; 23:2289-2303.

PMID: 38840832 PMC: 11152613. DOI: 10.1016/j.csbj.2024.05.025.


A Novel Nomogram for Identifying the Patients at Risk for Rapid Progression of Advanced Hormone-Sensitive Prostate Cancer.

Wu M, Pan C, He Y, Yang B Cancer Manag Res. 2023; 15:1015-1024.

PMID: 37746314 PMC: 10516215. DOI: 10.2147/CMAR.S425181.


Gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer.

Mou Z, Spencer J, Knight B, John J, McCullagh P, McGrath J Front Oncol. 2022; 12:914078.

PMID: 36033512 PMC: 9413154. DOI: 10.3389/fonc.2022.914078.


Replicability in cancer omics data analysis: measures and empirical explorations.

Wang J, Liang H, Zhang Q, Ma S Brief Bioinform. 2022; 23(5).

PMID: 35876281 PMC: 9487717. DOI: 10.1093/bib/bbac304.


References
1.
Mo S, Zhang L, Dai W, Han L, Wang R, Xiang W . Antisense lncRNA LDLRAD4-AS1 promotes metastasis by decreasing the expression of LDLRAD4 and predicts a poor prognosis in colorectal cancer. Cell Death Dis. 2020; 11(2):155. PMC: 7048743. DOI: 10.1038/s41419-020-2338-y. View

2.
J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

3.
Chen W, Tsai Y, Yeh H, Suau F, Jiang K, Shao A . Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer. Sci Signal. 2017; 10(492). DOI: 10.1126/scisignal.aam6826. View

4.
Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

5.
Munkley J, McClurg U, Livermore K, Ehrmann I, Knight B, McCullagh P . The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Sci Rep. 2017; 7(1):5249. PMC: 5507901. DOI: 10.1038/s41598-017-05489-5. View